Navigation Links
Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
Date:1/9/2014

EMERYVILLE, Calif., Jan. 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (NYSE: FRX) for MDX-8704.  MDX-8704 is a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release capsules) and donepezil HCl being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.

The milestone payments are for the successful completion of studies that support the planned New Drug Application (NDA) filing with the US Food and Drug Administration (FDA) for MDX-8704 by Forest in the first half of 2014.  These studies are based on a development plan agreed to by Adamas and the FDA prior to its license agreement with Forest.  Leveraging Adamas' know-how and intellectual property, the companies are collaborating on the development of the FDC, for which Forest has exclusive US commercialization rights.  Forest is responsible for all regulatory-related activities.  MDX-8704 is covered by multiple Adamas and Forest patents that extend to 2029.

Pursuant to their license agreement for development and commercialization of MDX-8704, Forest paid Adamas $65 million upfront in November 2012, and these $40 million payments are part of up to $95 million in subsequent development and regulatory approval milestones.  In addition, under the terms of the license agreement, Adamas will receive royalties beginning five years after launch on US net sales of FDC products and any additional memantine products for which Adamas' patents are listed in the FDA's Orange Book.

About Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
2. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
3. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
4. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
7. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
8. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
9. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
10. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
11. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical ... in opioid antagonists, announced today that it has ... respect to its naloxone-based opioid overdose reversal nasal ... received an additional commitment from the National Institute ... Institutes of Health ("NIH"), to fund a second ...
(Date:7/23/2014)... July 23, 2014 This September leading clinicians ... Las Vegas for DOCtalk 2014 ... author, forward thinker and private practitioner Dr. David ... to candidly discuss clinical and practice management efficiency and ... a unique opportunity to welcome fresh thinking and join ...
(Date:7/23/2014)... 23, 2014 Global healthcare company ... facing currency headwinds, increased price competition and supply disruptions ... Andrew Witty points out that the company is very ... reason to be confident about long-term prospects as well ... CFO Simon Dingemans adds that ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 32014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3
(Date:7/23/2014)... (July 23, 2014) Statins, a class of drugs ... patient,s risk of developing Barrett,s esophagus, according to a ... , the official journal of the American Gastroenterological Association. ... with statin use. , "Patients who received statins had ... Barrett,s esophagus compared to non-users," said study author Hashem ...
(Date:7/23/2014)... With cloud storage fast replacing traditional ... LeaseQ announced that that despite the lack of ... still see robust growth in computer hardware and ... technology equipment leasing, visit:, https://www.leaseq.com/computer-equipment-leasing , ... quoted as saying, “Although the growth of server ...
(Date:7/23/2014)... Hill, FL (PRWEB) July 23, 2014 The ... percent reduction in prescription drug deaths from 2010 to 2012. ... infamous for its minimal monitoring of access to some of ... the wrong hands. Florida’s law enforcement launched an initiative ... now nearly nonexistent compared to the 65 that existed in ...
(Date:7/23/2014)... 23, 2014 On July 21, 2014, My ... advocate Jack Tracey for an episode that spoke about the ... Deierlein asks Tracey to talk some about the formation of ... its mission, it was started right here in Charleston, originally ... was to help survivors of sexual abuse. Their purpose has ...
(Date:7/23/2014)... Five years ago, when the SSM St. ... options for babies diagnosed with a medical condition before birth. ... country for innovative fetal therapies. Since then, nearly 1,000 families ... for their babies in the womb, and the team has ... “A number of the babies we see are facing life-threatening ...
Breaking Medicine News(10 mins):Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2
... Ind., Nov. 21 Symmetry Medical Inc. (NYSE: SMA ... device industry and other medical markets, announced today that Brian S. ... Vice President and Chief Financial Officer, are scheduled to present at ... York Palace Hotel on Wednesday, December 3, 2008 at 12:30 p.m. ...
... smoking will receive big prizes during a special on-ice presentation ... Energy Center. The winners,were participants in The QuitCash Challenge, a ... The grand prize winner will ... cards from Gander Mountain. , ...
... study suggests , , FRIDAY, Nov. 21 (HealthDay News) -- The ... of asthma, new research suggests. , Babies born in autumn -- ... have almost a 30 percent increased risk of asthma compared to ... in the first December issue of the American Journal of ...
... Just three days after the,JUPITER trial results were presented ... by the New England Journal of Medicine, an,AlphaDetail survey ... anticipate a 14% increase in the use of drug ... risk patients. , ...
... travel nationwide to,ten top locations for Indoor Cycling / ... of innovative cycling training DVDs. The DVDs utilize,first-person ... selectable vocal coaching from industry experts. Sally Edwards,Ironman ... Matty Reed, US,triathlete champion and Olympian are just a ...
... Draeger Safety, Inc., located in,Pittsburgh PA, and ... products,provider, is countering what it believes are unsubstantiated ... of a patent,infringement on the popular Draeger PSS7000 ... Draeger has a ...
Cached Medicine News:Health News:Lucky Quitters to Receive Big Money in Stop-Smoking Contest 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Physicians Anticipate Higher Prescribing Based on JUPITER Study 2Health News:Global Ride Tours Best 12 Cities for SPINNING(R) or Indoor Cycling 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
5.5 pointed curved blade. Octagonal handle....
3 mm curved blade. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
Medicine Products: